At the time of writing, Ultragenyx Pharmaceutical Inc [RARE] stock is trading at $31.66, up 2.59%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The RARE shares have gain 2.46% over the last week, with a monthly amount glided 1.18%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
On June 06, 2024, upgrade upgraded it’s rating to Buy and revised its price target to $67 on the stock. RBC Capital Mkts started tracking the stock assigning an Outperform rating and suggested a price target of $77 on April 22, 2024. Wells Fargo initiated its recommendation with a Overweight and recommended $72 as its price target on December 08, 2023. In a note dated June 06, 2023, Evercore ISI upgraded an Outperform rating on this stock and boosted its target price from $60 to $80.
For the past year, the stock price of Ultragenyx Pharmaceutical Inc fluctuated between $25.81 and $57.99. Currently, Wall Street analysts expect the stock to reach $103.64 within the next 12 months. Ultragenyx Pharmaceutical Inc [NASDAQ: RARE] shares were valued at $31.66 at the most recent close of the market. An investor can expect a potential return of 227.35% based on the average RARE price forecast.
Analyzing the RARE fundamentals
According to Ultragenyx Pharmaceutical Inc [NASDAQ:RARE], the company’s sales were 610.16M for trailing twelve months, which represents an 13.24% jump. Gross Profit Margin for this corporation currently stands at 0.84% with Operating Profit Margin at -0.83%, Pretax Profit Margin comes in at -0.87%, and Net Profit Margin reading is -0.87%. To continue investigating profitability, this company’s Return on Assets is posted at -0.41, Equity is -2.37 and Total Capital is -0.5. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 5.84.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 31.03 points at the first support level, and at 30.39 for the second support level. However, for the 1st resistance point, the stock is sitting at 32.20, and for the 2nd resistance point, it is at 32.73.
Ratios To Look Out For
It is important to note that Ultragenyx Pharmaceutical Inc [NASDAQ:RARE] has a current ratio of 2.45. In addition, the Quick Ratio stands at 2.30 and the Cash Ratio stands at 0.63. Considering the valuation of this stock, the price to sales ratio is 5.00, the price to book ratio is 20.13.
Transactions by insiders
Recent insider trading involved Huizenga Theodore Alan, SVP, Chief Accounting Officer, that happened on Sep 18 ’25 when 64.0 shares were sold. Officer, KARAH PARSCHAUER completed a deal on Sep 12 ’25 to buy 2450.0 shares. Meanwhile, EVP and Chief Legal Officer Parschauer Karah Herdman sold 2450.0 shares on Sep 12 ’25.
